Description: HIV quantification is achieved through the use of a number of different assays which measure the amount of circulating viral RNA. Assays vary both in methods used to detect viral RNA as well as in ability to detect viral levels at lower limits. However, all employ some type of nucleic acid amplification technique to enhance sensitivity, and results are expressed as the HIV copy number.
Quantification assays of HIV plasma RNA are used prognostically to assess relative risk for disease progression and predict time to death, as well as to assess efficacy of anti-retroviral therapies over time.
HIV quantification is often performed together with CD4+T cell counts which provide information on extent of HIV induced immune system damage already incurred.
1. A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection.
2. Regular periodic measurement of plasma HIV RNA levels may be medically necessary to determine risk for disease progression in an HIV-infected individual and to determine when to initiate anti-retroviral treatment regimens.
3. In clinical situations where risk of HIV infection is significant and initiation of therapy is anticipated, a baseline HIV quantification may be performed. These situations include:
a. Persistence of borderline or equivocal serologic reactivity in an at-risk individual.
b. Signs and symptoms of acute retroviral syndrome characterized by fever, malaise, lymphadenopathy and rash in an at-risk individual.
1. Viral quantification may be appropriate for prognostic use including baseline determination, periodic monitoring, and monitoring of response to therapy. Use as a diagnostic test method is not indicated.
2. Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.
3. For prognosis including anti-retroviral therapy monitoring, regular, periodic measurements are appropriate. The frequency of viral load testing should be consistent with the most current Centers for Disease Control and Prevention guidelines for use of anti-retroviral agents in adults and adolescents or pediatrics.
4. Because differences in absolute HIV copy number are known to occur using different assays, plasma HIV RNA levels should be measured by the same analytical method. A change in assay method may necessitate re-establishment of a baseline.
5. Nucleic acid quantification techniques are representative of rapidly emerging & evolving new technologies. Users advised to remain current on FDA-approval status.
Assessment of CD4+ T cell numbers is frequently performed in conjunction with viral load determination. When used in concert, the accuracy with which the risk for disease progression and death can be predicted is enhanced.
Frequency Limitations: Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.
To review all requirements of this policy, please see:
CMS NCD listing by Chapter
Covered ICD-10 Codes.
||Human immunodeficiency virus [HIV] disease|
||HIV 2 as the cause of diseases classified elsewhere|
||Viral hepatitis complicating pregnancy, first trimester|
||Viral hepatitis complicating pregnancy, second trimester|
||Viral hepatitis complicating pregnancy, third trimester|
||Viral hepatitis complicating pregnancy, unsp trimester|
||Viral hepatitis complicating childbirth|
||Viral hepatitis complicating the puerperium|
||Other viral diseases complicating pregnancy, first trimester|
||Oth viral diseases complicating pregnancy, second trimester|
||Other viral diseases complicating pregnancy, third trimester|
||Other viral diseases complicating pregnancy, unsp trimester|
||Other viral diseases complicating childbirth|
||Other viral diseases complicating the puerperium|
||Human immunodef virus disease comp preg, first trimester|
||Human immunodef virus disease comp preg, second trimester|
||Human immunodef virus disease comp preg, third trimester|
||Human immunodef virus disease comp pregnancy, unsp trimester|
||Human immunodeficiency virus disease complicating childbirth|
||Human immunodef virus disease complicating the puerperium|
||Inconclusive laboratory evidence of human immunodef virus|
||Asymptomatic human immunodeficiency virus infection status|
The content and format of the following files and/or webpages are
copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All
recipients of these files agree not to distribute, reproduce and/or use the
information contained within, in any manner not expressly agreed upon by the
user and Wheaton Partners, LLC - dba CodeMap®.
All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and
Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap®
has made every reasonable effort to ensure the accuracy of the information
contained. However, the ultimate responsibility for correct
coding and claims submission lies with the provider of services. Both CMS and
Medicare contractor coverage policy information may change at any time.
CodeMap® makes no representation, warranty, or guarantee that this compilation
of coverage policy information is error-free or that the use of this information
will result in Medicare coverage and subsequent payment of claims. Final
coverage and payment of claims are subject to many factors exclusively
controlled by CMS and its contractors.